These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38492622)

  • 1. Targeting inflammatory signaling pathways with SGLT2 inhibitors: Insights into cardiovascular health and cardiac cell improvement.
    Alsereidi FR; Khashim Z; Marzook H; Gupta A; Al-Rawi AM; Ramadan MM; Saleh MA
    Curr Probl Cardiol; 2024 May; 49(5):102524. PubMed ID: 38492622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review regarding the article 'Targeting inflammatory signaling pathways with SGLT2 inhibitors: Insights into cardiovascular health and cardiac cell improvement'.
    He X; Yuan D
    Curr Probl Cardiol; 2024 Jun; 49(6):102563. PubMed ID: 38599557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors.
    Mashayekhi M; Safa BI; Gonzalez MSC; Kim SF; Echouffo-Tcheugui JB
    Trends Endocrinol Metab; 2024 May; 35(5):425-438. PubMed ID: 38423898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies.
    Naeimzadeh Y; Tajbakhsh A; Nemati M; Fallahi J
    Eur J Pharmacol; 2024 Sep; 978():176803. PubMed ID: 38950839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms.
    Mancini SJ; Boyd D; Katwan OJ; Strembitska A; Almabrouk TA; Kennedy S; Palmer TM; Salt IP
    Sci Rep; 2018 Mar; 8(1):5276. PubMed ID: 29588466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Sodium-Glucose Cotransporter-2 during Serum Deprivation Increases Hepatic Gluconeogenesis via the AMPK/AKT/FOXO Signaling Pathway.
    Lee J; Hong SW; Kim MJ; Lim YM; Moon SJ; Kwon H; Park SE; Rhee EJ; Lee WY
    Endocrinol Metab (Seoul); 2024 Feb; 39(1):98-108. PubMed ID: 38171209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibitors and AMPK: The road to cellular housekeeping?
    Safaie N; Masoumi S; Alizadeh S; Mirzajanzadeh P; Nejabati HR; Hajiabbasi M; Alivirdiloo V; Basmenji NC; Derakhshi Radvar A; Majidi Z; Faridvand Y
    Cell Biochem Funct; 2024 Jan; 42(1):e3922. PubMed ID: 38269506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.
    Koyani CN; Plastira I; Sourij H; Hallström S; Schmidt A; Rainer PP; Bugger H; Frank S; Malle E; von Lewinski D
    Pharmacol Res; 2020 Aug; 158():104870. PubMed ID: 32434052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia.
    Heimke M; Lenz F; Rickert U; Lucius R; Cossais F
    Cells; 2022 Oct; 11(19):. PubMed ID: 36231069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role.
    Fu J; Xu H; Wu F; Tu Q; Dong X; Xie H; Cao Z
    Int J Cardiol; 2022 Nov; 367():56-62. PubMed ID: 35931206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory Effects of SGLT2 Inhibitors-Targeting Inflammation and Oxidative Stress in Aging.
    Schönberger E; Mihaljević V; Steiner K; Šarić S; Kurevija T; Majnarić LT; Bilić Ćurčić I; Canecki-Varžić S
    Int J Environ Res Public Health; 2023 Aug; 20(17):. PubMed ID: 37681811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marein ameliorates diabetic nephropathy by inhibiting renal sodium glucose transporter 2 and activating the AMPK signaling pathway in db/db mice and high glucose-treated HK-2 cells.
    Guo Y; Ran Z; Zhang Y; Song Z; Wang L; Yao L; Zhang M; Xin J; Mao X
    Biomed Pharmacother; 2020 Nov; 131():110684. PubMed ID: 33152903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective Effect of SGLT2 Inhibitors.
    Pawlos A; Broncel M; Woźniak E; Gorzelak-Pabiś P
    Molecules; 2021 Nov; 26(23):. PubMed ID: 34885795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.
    Bellanti F; Lo Buglio A; Dobrakowski M; Kasperczyk A; Kasperczyk S; Aich P; Singh SP; Serviddio G; Vendemiale G
    World J Gastroenterol; 2022 Jul; 28(26):3243-3257. PubMed ID: 36051336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibitors as Calorie Restriction Mimetics: Insights on Longevity Pathways and Age-Related Diseases.
    Hoong CWS; Chua MWJ
    Endocrinology; 2021 Aug; 162(8):. PubMed ID: 33857309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors.
    Packer M
    J Am Soc Nephrol; 2020 May; 31(5):907-919. PubMed ID: 32276962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
    Zhou J; Zhu J; Yu SJ; Ma HL; Chen J; Ding XF; Chen G; Liang Y; Zhang Q
    Biomed Pharmacother; 2020 Dec; 132():110821. PubMed ID: 33068934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells.
    Uthman L; Kuschma M; Römer G; Boomsma M; Kessler J; Hermanides J; Hollmann MW; Preckel B; Zuurbier CJ; Weber NC
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1083-1094. PubMed ID: 33048256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease.
    Bonnet F; Scheen AJ
    Diabetes Metab; 2018 Dec; 44(6):457-464. PubMed ID: 30266577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.